How to bid on a Labeling Pilot for Pharmaceutical Products with DLA Troop Support Medical

What the agency is buying and why it matters

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain is looking for U.S. and international pharmaceutical manufacturers to join a voluntary labeling pilot program. This pilot aims to add country of origin information for finished dose forms, active pharmaceutical ingredients, and key starting materials to product labels, packaging, or documentation. This information could also vary by lot and be provided through a QR code or link.

This is market research to help DLA improve supply chain transparency, enhance traceability, and strengthen operational readiness. Understanding where pharmaceutical ingredients come from helps with contingency planning and risk modeling. This is not a solicitation for a contract, but an opportunity to inform future DLA initiatives and potentially shape how pharmaceutical products are sourced and labeled for government use.

Key dates and what happens at the deadline

The deadline for submitting your response to this Request for Information (RFI) is September 23, 2026, at 3:00 PM ET. All responses must be received by this time. Since this is market research, there will not be an award or contract issued directly from this RFI. The DLA will use the information gathered to inform its planning and evaluation of supply chain transparency methods.

Who this opportunity suits

This opportunity is suitable for U.S. and international pharmaceutical manufacturers. Specifically, firms that produce generic pharmaceutical products and have capabilities or systems for tracing active pharmaceutical ingredients (API) and key starting materials (KSM) would be a good fit. Companies willing to explore voluntary labeling enhancements and share data on product origins should consider responding. This falls under the healthcare category, focusing on pharmaceutical supply chain and manufacturing.

How to respond

To respond, you need to prepare a written submission in PDF or Word format. This document should address specific points requested by the DLA, including your company name, CAGE code, contact information, a description of your pharmaceutical products, your willingness to participate in the pilot, and your ability to provide the requested country of origin information by lot. You should also detail any existing traceability capabilities, expected timelines for modifications, concerns, cost impacts, and recommendations for the pilot.

Email your completed response to Charles T. Reimer at [email protected]. To access the original source document for full details, click “View original source” on the portal. If the first click takes you to the homepage, click it again to go directly to the bid. You may need a free account to view all documents, though this is not always required.

Practical tips for preparing a competitive response

Clearly and concisely address each point requested in the RFI. Provide specific examples of your current traceability systems and how they could support the pilot's requirements. If you have experience with similar labeling initiatives or regulatory approvals, highlight this expertise.

Be realistic about the estimated production or administrative impact and the timeline for implementing labeling modifications. Providing a well-thought-out assessment of potential challenges and costs, along with constructive recommendations for the pilot's structure, can demonstrate your firm's readiness and commitment. Ensure your contact information is accurate for any follow-up questions from the DLA.